Intestinal Perforation due to Neutropenic Enterocolitis in a Patient Treated with Bevacizumab for Ovarian Cancer. (17th June 2020)

• Record Type: Journal Article
• Authors: Sasaki, Akinori; Harano, Kenichi; Kogawa, Takahiro; Matsubara, Nobuaki; Naito, Yoichi; Hosono, Ako; Mukai, Hirofumi; Yoshino, Takayuki; Mukohara, Toru
• Other Names: Cives Mauro Academic Editor.
• Is Part Of: Case reports in oncological medicine. Volume 2020(2020)
• Publication Date: 2020-06-17
• Subjects: Oncology -- Periodicals; Tumors -- Periodicals; Oncology -- Case studies -- Periodicals; Neoplasms; Oncology; Tumors; Electronic journals; Periodicals; Case studies; Periodicals; Case Reports; Fulltext; Internet Resources; Periodicals; 616.994
• DOI: 10.1155/2020/7231358
• Languages: English
• ISSNs: 2090-6706

Abstract

Abstract : Intestinal perforation is a rare adverse event of antineoplastic therapy. However, once it occurs, it is potentially fatal. This report describes a case of intestinal perforation caused by bevacizumab in a patient with ovarian cancer who concurrently developed neutropenic enterocolitis. A 66-year-old woman diagnosed with metastatic ovarian cancer received combination chemotherapy with carboplatin, gemcitabine, and bevacizumab. On day 14, she developed grade 4 pancytopenia and febrile neutropenia, which resulted in neutropenic enterocolitis and intestinal perforation. Emergency surgery was performed, and an intestinal perforation found in the ascending colon was closed. Postoperatively, she developed an intra-abdominal abscess requiring peritoneal drainage. She was discharged from the hospital on recovery.